Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas With Dysregulation of the mTOR Pathway

NCT02987959 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT02987959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02987959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas With Dysregulation of the mTOR Pathway
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
February 21, 2017
Completion date
July 24, 2020
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

soft-tissue sarcoma